# STUDY00016033 (NCT04251715)

> mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04251715
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: OHSU Knight Cancer Institute
- Conditions: Liver and Intrahepatic Bile Duct Carcinoma; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Intrahepatic Cholangiocarcinoma
- Interventions: Dexamethasone; Floxuridine; Implanted Medical Device; Irinotecan; Leucovorin; Oxaliplatin; Quality-of-Life Assessment
- Enrollment: 5
- Primary outcome: Frequency of Abnormal Liver Function
- Primary outcome: Disease Control Rate (DCR) - During HAI+SYS

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=study00016033-nct04251715